Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of ReproCELL Incorporated. A complete text table follows the diagram.
Research support supplies most revenue, but both segments are loss-making as the company invests in medical programs and iPS-cell capabilities.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research Support Business | 1 | 887M | 91.1% of reported total |
| Medical Business | 1 | 86.6M | 8.9% of reported total |
| Revenues From External Customers | 2 | 974M | Reported six-month total · ¥974M |
| Operating loss | 2 | 547M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.5B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research Support Business | Revenues From External Customers | 887M |
| Medical Business | Revenues From External Customers | 86.6M |
| Revenues From External Customers | Operating costs & expenses | 974M |
| Operating loss | Operating costs & expenses | 547M |